Prodrugs and active metabolites among antidepressive compounds;Antidepresszánsok és aktív metabolitjaik sorsa a szervezetben

Neuropsychopharmacologia Hungarica

Volumn 13, Issue 2, 2011, Pages 103-110

  Tekes, Kornélia ^a   Hashemi, Farzad ^a   Szegi, Péter ^a   Sótonyi, Péter ^a   Laufer, Rudolf ^a   Kalász, Huba ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Active metabolite; Antidepressant; Cyp isoenzymes in brain; Pharmacodynamic interaction; Pharmacokinetics

Indexed keywords

ACETANILIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; DESIPRAMINE; DRUG METABOLITE; FEXOFENADINE; FLUOXETINE; FLUVOXAMINE; GINKGO BILOBA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MORPHINE 6 GLUCURONIDE; NEFAZODONE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PRODRUG; SULFAMIDOCHRYSOIDINE; SULFONAMIDE; TERFENADINE; TRIMIPRAMINE; UNINDEXED DRUG;

ARTICLE; BLEEDING; BRADYCARDIA; DEMETHYLATION; DEPRESSION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HUMAN; HYDROXYLATION; HYPOTENSION; KNOWLEDGE BASE; MAXIMUM PLASMA CONCENTRATION; OXIDATION; PHARMACODYNAMICS;

ANTIDEPRESSIVE AGENTS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PRODRUGS;

EID: 79959831909     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Abbott NJ, Ronnback L, Hansson E. (2006) Astrocyte endothelial interactions at the blood brain barrier. Nat Rev Neurosci 7(1):41-53.
2. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. (2005) Drug metabolism and pharmacokinetics, the blood brain barrier, and central nervous system drug discovery. NeuroRx, 2(4):554-571.
3. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. (2004) Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol 24(1):4-10.
4. Dutheil F, Beaune P, Loriot MA.(2008) Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochromee P450 enzymes in normal and pathological human brain. Biochimie 90(3):426-436.
5. Frecska E.(2010) Trazodone--its multifunctional mechanism of action and clinical use. Neuropsychopharmacol Hung, 12:477-482. Hungarian.
6. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590.
7. Goodman &Gilman's Manual of Pharmacology and Therapeutics (eds, Brunton,L.L., Parker, K.L., McGraw Hill Medical, 2008) pp 278-296.
8. Haining RL, Nichols Haining M. (2007) Cytochromee P450 catalyzed pathways in human brain:metabolism meets phar-macology or old drugs with new mechanism of action? Pharmacol Ther. 113(3):537-545.
9. Harris BE, Carpenter JT, Diasio RB.(1991) Severe 5 fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68:499-501.
10. Katzung, B.G.(2006) Basic and clinical pharmacology, Lange, 10th ed., Mc Graw Hill, Chapter 30: Antidepressant drugs.
11. Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, Williams DE, Pajewski NM, Wang T, Hines RN. (2007) Identification and functional analysis of common human flavin containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther 320:266-273.
12. MICROMEDEX® 1.0 (Healthcare Series), 1974-2011 Thomson Reuters.
13. Nissbrandt H, Bergquist F, Jonason J, Engberg G. Inhibition of cytochromee P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway? Synapse 2001; 40(4):294-301.
14. Sárosi A, Gonda X, Balogh G, Székely A, Sasvári M, Faludi G (2008) [Gender differences in the neurocognitive components of depression]. Neuropsychopharmacol Hung 10(4):191-9. Hungarian.
15. Spuch C, Carro E.(2011)The p75 neurotrophin receptor localization in blood-CSF barrier: expression in choroid plexus epithelium. BMC Neurosci. 11;12(1):39.
16. Sümegi A., Somoskövi Cs. (2010) Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism. Neuropsychopharmacol Hung, 2010;12:469-474.
17. Wang Y., Bell, J.C., Strobel H.W.(2009) Sites of extra hepatic metabolism in: Handbook of Drug Metabolism, eds P.G. Pearson and L.C. Wienkers, 2nd ed., Informa Healthcare, New York, London, pp 327-353.
18. Williams RT. (1959) Detoxication Mechanisms. 2nd Edition, New York: John Wiley & Sons Inc.
19. Wolburg H, Lippoldt A. (2002) Tight junctions of the blood brain barrier: development, composition and regulation. Vascul Pharmacol, 38(6):323-337.
20. Zupancic M, Guilleminault C. (2006) Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20: 981-92.
21. http://www.drugbank.ca
22. http://www.pharmindex.hu